Loading...

Revolutionizing the understanding of treatment response to improve patient outcomes

AIQ ANNOUNCEMENTS

February 16, 2021

We are proud to announce that our latest published collaboration with Pfizer, Wayne State University Karmanos Cancer Institute, University of Wisconsin Carbone Cancer Center, and Rutgers Cancer Institute, has been included in the Best of Journal of Clinical Oncology 2021 Genitourinary Cancer Edition - The title of the publication is "Exploring Spatial-Temporal Changes in 18F-Sodium Fluoride PET/CT and Circulating Tumor Cells in Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide."  The study demonstrates the unique intelligence AIQ technology provides related to intra-patient treatment response heterogeneity and how that heterogeneity impacts patient clinical response.

Delivering actionable intelligence that enhances understanding of treatment response for complex diseaseS 

The AIQ Solutions medical software platform can assist in allowing researchers to understand disease better and clinicians to manage patients more effectively.

Heterogeneity understood through AIQ Solutions intelligence

We provide detailed information highlighting treatment response heterogeneity to build our comprehensive Treatment Response Assessment (TRA).
LEARN MORE
1

Improve patient
management

Optimize therapy through early identification of sub-optimal treatment response and direct targeting of treatment resistance.
2

Reduce healthcare costs associated with INeffective treatments

Extend benefit of effective therapies, avoid unnecessary use of expensive combination therapies, and reduce spending on ineffective therapies.
3

Streamline drug development

Make more efficient go/no-go decisions by better understanding pharmacodynamic effects and mechanisms of resistance in shorter, smaller studies.

AIQ technology can be applied in a broad range of clinical scenarios

Below are a few examples of how our treatment response assessments have been applied.

Type of therapy

-    Immunotherapy    
-    Targeted radionuclide therapy
-    Chemotherapy
-    Hormone-receptor targeting  
-    Theranostics

DISEASE Type

-    Metastatic prostate cancer 
-    Metastatic breast cancer  ‍
‍-    GI neuroendocrine tumors
-    Metastatic melanoma
-    Multiple myeloma
-    Leukemia/ Hematologic Cancers
‍-    Osteoporosis
-    Head-and-neck cancer
-    Lung cancer

SITE OF METASTAsIS

-    Bone    
-    Liver    
-    Lung    
-    Lymph nodes

Types of scans/tracers

-    PSMA
-    FDG
-    Gallium (Ga)-DOTATATE
-    NaF
-    Others (FLT, FES, [18F]F-AraG)

organs for toxicity

-    Liver
-    Kidney
-    Bowel

Learn more about AIQ

For more information on AIQ treatment response solutions

Contact our Team
PAGE CITATIONSOUr Productclinical studiespatient managementPARTNERSHIPSAbout usresources
Copyright © 2020, AIQ Global, Inc. All Rights Reserved.

AIQ's software has been cleared for clinical use under 510(k) K173444. For details, including the applicable Indications for Use,
see: https://www.accessdata.fda.gov/scripts/cdrh/cfcodes/cfPMN/pmn.cfm?ID=K173444